Bicara Therapeutics Inc. (BCAX)
NASDAQ · Manufacturing · Pharmaceutical preparations
BCAX price, last 12 months
Key stats
- Previous close
- $9.38
- Open
- $9.40
- Day range
- $9.05 – $9.55
- 52-week range
- $7.87 – $30.99
- Volume
- 844.7K
- Avg volume (20 days)
- 2.3M
- Market cap
- $665.2M
Performance
Technicals and fundamentals
About Bicara Therapeutics Inc.
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $665.2M